Posts Tagged ‘liver cancer’

Omega 3 fish oil potential anti cancer linked with decrease in tumour formation.

Thursday, July 28th, 2011

Suppressed liver tumorigenesis in fat-1 mice with elevated omega-3 fatty acids is associated with increased omega-3 derived lipid mediators and reduced TNF-α.

Weylandt KH, Krause LF, Gomolka B, Chiu CY, Bilal S, Nadolny A, Waechter SF, Fischer A, Rothe M, Kang JX.
Source

Laboratory for Lipid Medicine and Technology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. karsten.weylandt@charite.de
Abstract
Liver tumors, particularly hepatocellular carcinoma (HCC), are a major cause of morbidity and mortality worldwide. The development of HCC is mostly associated with chronic inflammatory liver disease of various etiologies. Previous studies have shown that omega-3 (n-3) polyunsaturated fatty acids (PUFAs) dampen inflammation in the liver and decrease formation of tumor necrosis factor (TNF)-α. In this study, we used the fat-1 transgenic mouse model, which endogenously forms n-3 PUFA from n-6 PUFA to determine the effect of an increased n-3 PUFA tissue status on tumor formation in the diethylnitrosamine (DEN)-induced liver tumor model. Our results showed a decrease in tumor formation, in terms of size and number, in fat-1 mice compared with wild-type littermates. Plasma TNF-α levels and liver cyclooxygenase-2 expression were markedly lower in fat-1 mice. Furthermore, there was a decreased fibrotic activity in the livers of fat-1 mice. Lipidomics analyses of lipid mediators revealed significantly increased levels of the n-3 PUFA-derived 18-hydroxyeicosapentaenoic acid (18-HEPE) and 17-hydroxydocosahexaenoic acid (17-HDHA) in the livers of fat-1 animals treated with DEN. In vitro experiments showed that 18-HEPE and 17-HDHA could effectively suppress lipopolysacharide-triggered TNF-α formation in a murine macrophage cell line. The results of this study provide evidence that an increased tissue status of n-3 PUFA suppresses liver tumorigenesis, probably through inhibiting liver inflammation. The findings also point to a potential anticancer role for the n-3 PUFA-derived lipid mediators 18-HEPE and 17-HDHA, which can downregulate the important proinflammatory and proproliferative factor TNF-α.

PMID: 21421544 [PubMed - in process] PMCID: PMC3106436 [Available on 2012/6/1]

Omega 3 EPA success potential in the treatment and prevention of bowel cancer

Saturday, July 9th, 2011

Omega 3 fish oil EPA success potential in the treatment and prevention of bowel cancer

RESEARCHERS from  Leeds University Yorkshire are planning to carry out a series of experiments to investigate if omega 3 fish oil specifically EPA can prevent or treat the spread of bowel cancer to the liver.

Scientists from Leeds University will test a naturally occurring omega-3 fish oil component.

Gastroenterologist Prof Mark Hull, from the Leeds Institute of Molecular Medicine, will design a clinical trial to test the effect in humans at risk of or with bowel cancer which has spread to the liver.

The research is being funded by the charity Yorkshire Cancer Research and follows a previous trial in Leeds that showed that fish oil, or pure Eicosapentaenoic Acid (EPA), may prevent bowel polyps, the precursors of cancer.

Prof Hull said: “We and others have already demonstrated that EPA omega3 may  have beneficial effects at a later stage after development of malignancy.

TakeOmega3 has 750mg EPA AND 50mg DHA per capsule it is an 85% concentrate most other omega3’s are around 40%  and contain other oils within the capsule the key to successful treatment of this and other medical conditions  is to use as high a concentration of EPA as possible  , uniquely it is the highest concentration EPA supplement available and is manufactured in MHRA facilities thus adheering to the highest possible standards normally only applied to pharmaceutical drugs.

Bowel Cancer or Colorectal around 110 new cases of colorectal cancer are diagnosed each day in the UK and it is the third most common cancer after breast and lung. In 2008 there were 39,991 new cases of large bowel cancer registered in the UK: around two-thirds (25,551) in the colon and one-third (14,440) in the rectum

Scotland has one of the highest rates of bowel cancer worldwide, which has been linked to a range of social and economic factors such as significant deprivation, poor diet choices, high alcohol consumption, lack of exercise and an ageing population.
Around 3,500 people are diagnosed with bowel cancer each year in Scotland and over 1,500 die of the disease.
Bowel cancer is the third most common cancer in the Western world and is the second biggest cause of cancer-related death after lung cancer. However, the disease is highly treatable if detected early, with a 90% survival rate over five years.
Great Britain Flag
Made in the UK - Take Omega 3 Suspendisse lacinia ultricies justo, at ultricies nisi tempus ac. Cras sed vehicula metus. Phasellus...